Strategic Financial Concepts LLC Takes Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Strategic Financial Concepts LLC bought a new position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 11,250 shares of the biotechnology company’s stock, valued at approximately $141,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. SG Americas Securities LLC grew its position in shares of Rocket Pharmaceuticals by 796.2% in the fourth quarter. SG Americas Securities LLC now owns 54,921 shares of the biotechnology company’s stock valued at $690,000 after purchasing an additional 48,793 shares during the last quarter. Jennison Associates LLC boosted its stake in Rocket Pharmaceuticals by 72.6% during the 4th quarter. Jennison Associates LLC now owns 70,304 shares of the biotechnology company’s stock valued at $884,000 after purchasing an additional 29,564 shares during the period. Mirador Capital Partners LP grew its holdings in Rocket Pharmaceuticals by 403.9% in the 4th quarter. Mirador Capital Partners LP now owns 84,529 shares of the biotechnology company’s stock valued at $1,063,000 after buying an additional 67,755 shares during the last quarter. First Turn Management LLC increased its position in Rocket Pharmaceuticals by 10.8% in the 3rd quarter. First Turn Management LLC now owns 621,306 shares of the biotechnology company’s stock worth $11,476,000 after buying an additional 60,317 shares during the period. Finally, Walleye Capital LLC acquired a new position in shares of Rocket Pharmaceuticals during the third quarter worth approximately $2,556,000. Institutional investors own 98.39% of the company’s stock.

Insider Buying and Selling at Rocket Pharmaceuticals

In other Rocket Pharmaceuticals news, CEO Gaurav Shah sold 11,091 shares of the company’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $13.05, for a total transaction of $144,737.55. Following the sale, the chief executive officer now directly owns 707,328 shares of the company’s stock, valued at approximately $9,230,630.40. This represents a 1.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 14,386 shares of company stock worth $185,345 over the last three months. Company insiders own 28.50% of the company’s stock.

Rocket Pharmaceuticals Trading Down 0.2 %

Shares of RCKT opened at $9.86 on Thursday. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. The stock has a market cap of $898.84 million, a PE ratio of -3.59 and a beta of 0.98. Rocket Pharmaceuticals, Inc. has a 1 year low of $9.33 and a 1 year high of $31.47. The stock has a 50 day simple moving average of $11.47 and a 200-day simple moving average of $15.60.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Wedbush assumed coverage on shares of Rocket Pharmaceuticals in a research note on Monday, December 30th. They issued an “outperform” rating and a $32.00 price objective on the stock. Canaccord Genuity Group restated a “buy” rating and issued a $39.00 price target on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 19th. Leerink Partners dropped their price objective on shares of Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating on the stock in a report on Tuesday, November 19th. Chardan Capital reiterated a “buy” rating and issued a $62.00 target price on shares of Rocket Pharmaceuticals in a research note on Monday, November 18th. Finally, Jefferies Financial Group started coverage on Rocket Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $29.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $47.27.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.